Payment overview · 2025
General Payments
$1,019.34
69 reported records · 20 companies
Healthcare provider profile · identity verified
Jennifer A Camas, MD
Allopathic & Osteopathic Physicians|Pediatrics · BROWNSVILLE, KY · NPI 1902828114
Verified facts
What the public records show
CMS Open Payments records show Jennifer A Camas, MD received $1,019.34 in general payments during 2025 across 69 reported records.
Novartis Pharmaceuticals Corporation accounted for 21.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Eliquis, Entresto, Mounjaro, Qulipta, Trelegy Ellipta, Ubrelvy, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Ubrelvy by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Auvelity by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $215.07 | 21.1% | 11 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $182.27 | 17.9% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $156.08 | 15.3% | 20 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $106.33 | 10.4% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $73.61 | 7.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.01 | 3.1% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $30.82 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.52 | 2.5% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $23.22 | 2.3% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.73 | 2.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.69 | 1.7% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $17.60 | 1.7% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $17.57 | 1.7% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.22 | 1.6% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.68 | 1.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.12 | 1.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.04 | 1.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.81 | 1.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.48 | 1.3% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.47 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,008.05 | 68 |
| Education | $11.29 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $215.07 | 11 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $182.27 | 12 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $106.33 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.63 | 13 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $74.74 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $73.61 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $63.45 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.01 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | Regeneron Healthcare Solutions, Inc. | $30.82 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.52 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $23.22 | 1 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $14.12 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.48 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $13.47 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $13.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 135 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 16 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
135 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
102 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 227 | 51 |
| Levothyroxine Sodium | Levothyroxine Sodium | 211 | 53 |
| Montelukast Sodium | Montelukast Sodium | 208 | 46 |
| Atorvastatin Calcium | Atorvastatin Calcium | 170 | 52 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 162 | 42 |
| Furosemide | Furosemide | 149 | 31 |
| Pregabalin | Pregabalin | 148 | 27 |
| Losartan Potassium | Losartan Potassium | 141 | 35 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 33 |
| Mounjaro | Tirzepatide | 135 | 26 |
| Trazodone Hcl | Trazodone Hcl | 126 | 30 |
| Gabapentin | Gabapentin | 116 | 23 |
| Spironolactone | Spironolactone | 115 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 113 | 23 |
| Metformin Hcl | Metformin Hcl | 112 | 26 |
| Carvedilol | Carvedilol | 102 | 24 |
| Entresto | Sacubitril/Valsartan | 102 | 21 |
| Potassium Chloride | Potassium Chloride | 101 | 24 |
| Lisinopril | Lisinopril | 99 | 27 |
| Repatha Syringe | Evolocumab | 97 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 26 |
| Famotidine | Famotidine | 93 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 81 | 21 |
| Farxiga | Dapagliflozin Propanediol | 73 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 18 |
| Fluconazole | Fluconazole | 68 | 48 |
| Clonazepam | Clonazepam | 66 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 18 |
| Simvastatin | Simvastatin | 61 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 16 |
| Ezetimibe | Ezetimibe | 58 | 13 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 53 | 53 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 13 |
| Glipizide | Glipizide | 52 | 13 |
| Bupropion Xl | Bupropion Hcl | 51 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 19 |
| Jardiance | Empagliflozin | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | suppressed |
| Xarelto | Rivaroxaban | 46 | suppressed |
| Mirtazapine | Mirtazapine | 45 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Allopurinol | Allopurinol | 42 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 42 | 12 |
| Repatha Sureclick | Evolocumab | 42 | 14 |
| Alprazolam | Alprazolam | 41 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 41 | 11 |
| Lorazepam | Lorazepam | 40 | suppressed |
| Ondansetron Odt | Ondansetron | 40 | 16 |
| Buspirone Hcl | Buspirone Hcl | 38 | 11 |
| Colestipol Hcl | Colestipol Hcl | 38 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Meloxicam | Meloxicam | 38 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 15 |
| Ozempic | Semaglutide | 37 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 37 | 14 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 36 | 36 |
| Eliquis | Apixaban | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 36 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 36 | 11 |
| Prazosin Hcl | Prazosin Hcl | 36 | 11 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Praluent Pen | Alirocumab | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 30 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 29 | 16 |
| Ubrelvy | Ubrogepant | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 20 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Linzess | Linaclotide | 26 | suppressed |
| Trulance | Plecanatide | 26 | suppressed |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Nystatin | Nystatin | 24 | 11 |
| Qulipta | Atogepant | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Tirosint | Levothyroxine Sodium | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 16 |
| Torsemide | Torsemide | 18 | suppressed |
| Cefdinir | Cefdinir | 17 | 17 |
| Dexamethasone | Dexamethasone | 17 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Dupixent Syringe | Dupilumab | 16 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Baclofen | Baclofen | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Metaxalone | Metaxalone | 14 | suppressed |
| Roflumilast | Roflumilast | 14 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Acyclovir | Acyclovir | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Trokendi Xr | Topiramate | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Humira(Cf) Pen | Adalimumab | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Procto-Med Hc | Hydrocortisone | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,019.34 · 69 records | Novartis Pharmaceuticals Corporation | Auvelity, BREZTRI, CeQur Simplicity, DUPIXENT, ELIQUIS, ENTRESTO, Jornay PM, Kerendia, Korlym, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ohtuvayre, QULIPTA, Qelbree, REPATHA, TONMYA, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYEPTI, Veozah, YUPELRI, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error